Drug Trial Radar · NCT00433589
Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes
Last checked: Nov 19, 2026Latest source record: Nov 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,600
Planned (sponsor's estimate)
Start
Feb 2007
Primary completion
Mar 2020
Study completion Mar 2020
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- Collaborators
- Agendia; Breast International Group; Roche Pharma AG; Novartis; Sanofi
- First posted
- Feb 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving chemotherapy and hormone therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether genetic testing is more effective than clinical assessment in determining the need for chemotherapy in treating breast cancer. PURPOSE: This randomized phase III trial is studying genetic testing to see how well it works compared with clinical assessment in determining the need for chemotherapy in women with breast cancer that is either node-negative or involves no more than 3 lymph nodes.
Conditions
- Breast Cancer
Interventions
anthracycline-basedDrug
docetaxel and capecitabineDrug
tamoxifenDrug
LetrozoleDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Distant metastasis-free survival at 5 yearsTime frame: from enrollment/randomization
- Disease-free survival (DFS)Time frame: from enrollment/randomization
- DFSTime frame: from enrollment/randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.